Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1269-1274

  Ito, Y ^a   Kobayashi, T ^b   Takeda, T ^a   Komoike, Y ^a   Wakasugi, E ^a   Tamaki, Y ^a   Tsujimoto, M ^c   Matsuura, N ^d   Monden, M ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; p21; p53; Thyroid; Western blotting

Indexed keywords

PROTEIN P21; PROTEIN P53;

ARTICLE; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; THYROID GLAND;

EID: 0029844146     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.528     Document Type: Article

References (31)

1. CARCANGIU MI, ZAMPI G AND ROSAI D. (1984). Poorly differentiated ('insular') thyroid carcinoma. Am. J. Surg. Pathol., 8, 655 - 688.
2. DIGIUSEPPE JA, REDSTON MS, YEO CJ, KERN SE AND HRUBAN RH. (1995). p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am. J. Pathol., 147, 884 - 888.
3. DOBASHI Y, SAKAMOTO A, SUGIMURA H, MERNYEI M, MORI M, OYAMA T AND MACHINAMI R. (1993). Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am. J. Surg. Pathol., 17, 375 - 381.
4. DONGHI R, LONGONI A, PILOTTI S, MICHIELI P, PORTA GD AND PIEROTTI MA. (1993). Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest., 91, 1753 - 1760.
5. EL-DEIRY W, TOKINO T, VELCULESCU VE, LEVY DB, PARSONS R, TRENT JM, LIN D, MERCER WE, KINZLER KW AND VOGELSTEIN B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817 - 825.
6. 1 arrest and apoptosis. Cancer Res., 54, 1169 - 1174.
7. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55, 2910 - 2919.
8. FAGIN JA, MATSUO K, KARMAKER A, CHEN DL, TANG SH AND KOEFFLER HP. (1993). High prevalence of mutation of p53 gene in poorly differentiated human thyroid carcinomas. (1993). J. Clin. Invest., 91, 179 - 184.
9. FINLAY CA, HINDS PW, TAN TH, ELIYAHU D, OREN M AND LEVINE AJ. (1988). Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell Biol., 8, 531 - 539.
10. FLORES-ROZAS H, KELMAN Z, DEAN FB, PAN ZQ, HARPER JW, ELLEDGE SJ, O'DONNELL M AND HURWITZ J. (1994). Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc. Natl Acad. Sci. USA, 91, 8655 - 8659.
11. GRONTAJASKI RM, GOLDBERG AL AND PARDEE AB. (1984). Energy requirement for degradation of tumor-associated protein p53. Mol. Cell Biol., 4, 442 - 448.
12. 1 cyclin-dependent kinases. Cell, 75, 805 - 816.
13. HOLMS R AND NESLAND JM. (1994). Retinoblastoma and p53 tumor suppressor gene protein expression in carcinomas of the thyroid gland. J. Pathol., 172, 267 - 272.
14. ITO T, SEYAMA T, MIZUNO T, TSUYAMA N, HAYASHI T, HAYASHI Y, DOHI K, NAKAMURA N AND AKIYAMA M. (1992). Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res., 52, 1369 - 1371.
15. ITO Y, KOBAYASHI T, TAKEDA T, KOMOIKE Y, WAKASUGI E, TAMAKI Y, UMESHITA K, MONDEN T AND MONDEN M. (1996). Immunohistochemical study of cell cycle modulators in the G1-S transition in clinical breast cancer tissue. Breast Cancer, (in press).
16. WAF1/CIP1 in human brain tumors. Oncogene, 11, 2021 - 2028.
17. LI R, WAGA S, HANNON GJ, BEACH D AND STILLMANN B. (1994). Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature, 371, 534-537.
18. LI XJ, PUIG PL, SALMON RJ, THOMAS G AND HAMELIN R. (1995). Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene, 10, 599 - 601.
19. MICHIELI P, CHEDID M, LIN D, PIERCE H, MERCER WE AND GIVOL D. (1994). Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54, 3391 - 3394.
20. OHUE M, TOMITA N, MONDEN T, FUJITA M, FUKUNAGA M, TAKAMI K, YANA I, OHNISHI T, ENOMOTO T, INOUE M, SHIMANO T AND MORI T. (1994). A frequent alteration of p53 gene in carcinoma in ademona of colon. Cancer Res., 54, 4798-4804.
21. PAPOTTI M, MICCA FB, FAVERO A, PALESTINI N AND BUSSOLATI G. (1993). Poorly differentiated thyroid carcinomas with primordial cell component. A group of agressive lesions sharing insular, trabecular and solid patterns. Am. J. Surg. Pathol., 8, 291-301.
22. SAKAMOTO A, KASAI N AND SUGANO H. (1983). Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer, 52, 1849 - 1855.
23. SERRANO M, HANNON GJ AND BEACH D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ CDK4. Nature, 366, 704-707.
24. SHEIKH MS, LI XS, CHEO JC, SHAO ZM, ORDONEZ JV AND FONTANA JA. (1994). Mechanisms of regulation of WAF1/CIP1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene, 9, 3407-3415.
25. SHIOHARA M, EL-DEIRY WS, WADA M, NAKAMAKI T, TAKEUCHI S, YANG R, CHEN DL, VOGELSTEIN B AND KOEFFLER HP, (1994). Absence of WAF1 mutation in a variety of human malignancies. Blood, 84, 3781-3784.
26. SOARES P, CAMESELLE-TEIJEIRO J AND SOBRINHO-SIMOES M. (1994). Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology, 24, 205 - 210.
27. WRIGHT PA, LEMOINE NR AND GORETZKI PE. (1991). Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, hut not in primary thyroid tumors. Oncogene, 6, 1693-1697.
28. WYNFORD-THOMAS D. (1992). p53 in tumor pathology: can we trust immunohistochemistry? J. Pathol., 166, 329 - 330.
29. XIONG Y, HANNON GJ, ZHANG H, CASSO D, KOBAYASHIR AND BEACH D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
30. YOSHIMOTO K, IWAHANA H, FUKUDA A, SANO T, SAITO S AND ITAKURA M. (1992). Role of p53 mutation in endocrine tumorigenesis: mutation detection by polymerase chain reaction single strand conformation polymorphism. Cancer Res., 52, 5061-5064.
31. ZHANG W, GRASSO L, MCCLAIN CD, GAMBEL AM, CHA Y, TRAVALI S, DEISSEROTH AB AND MERCER WE. (1995). p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res., 55, 668 - 674.